Skip to main content
48°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corp
(NY:
CVM
)
0.5998
-0.0047 (-0.78%)
Streaming Delayed Price
Updated: 9:38 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cel-Sci Corp
< Previous
1
2
3
4
5
6
Next >
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 28, 2023
Via
Benzinga
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
December 27, 2023
CEL-SCI just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Why CEL-SCI (CVM) Shares Are Down 20%
July 18, 2023
CEL-SCI Corporation (NASDAQ: CVM) shares are trading lower by 21.3% to $2.25 Tuesday morning after the company priced its public offering of 2.5 million shares at $2.00 per share.
Via
Benzinga
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 04, 2023
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 04, 2023
Via
Benzinga
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
December 04, 2023
CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the...
Via
Benzinga
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
December 04, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
November 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
November 16, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Issues Letter to Shareholders
October 30, 2023
From
CEL-SCI Corporation
Via
Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
October 24, 2023
From
CEL-SCI Corporation
Via
Business Wire
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
October 23, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
October 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
October 05, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
September 26, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
August 11, 2023
From
CEL-SCI Corporation
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
July 31, 2023
On Monday, 27 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
Friday's session saw 59 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
CEL-SCI Announces Closing of Public Offering
July 20, 2023
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 18, 2023
Via
Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
US Stocks Mixed; Bank of America Tops Q2 Views
July 18, 2023
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 70 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 34,655.10 while the NASDAQ fell 0.38% to...
Via
Benzinga
TDOC Stock Alert: Teladoc Doubles Down on Microsoft AI Partnership
July 18, 2023
Teladoc (TDOC) stock is on the move Tuesday as the company expands its Microsoft (MSFT) AI partnership to enhance Teladoc Health Solo.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.